Evidence map›Paper›PMID 36741450›Full record

ArticlePNAS nexus2022

No association of a risk variant for severe COVID-19 with HIV protection in three cohorts of highly exposed individuals.

Manuela Sironi, Rachele Cagliani, Mara Biasin, Sergio Lo Caputo, Irma Saulle, Diego Forni, Luis Miguel Real, Juan Antonio Pineda, Almudena Exposito, María Eugenia Saez and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PNAS nexus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 3 countries.

Manuela SironiScientific Institute IRCCS E. MEDEA, Bioinformatics, Bosisio Parini, 23842 Lecco, Italy.ORCID https://orcid.org/0000-0002-2267-5266
Rachele CaglianiScientific Institute IRCCS E. MEDEA, Bioinformatics, Bosisio Parini, 23842 Lecco, Italy.ORCID https://orcid.org/0000-0003-2670-3532
Mara BiasinLaboratory of Immunobiology, Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, 20157 Milan, Italy.
Sergio Lo CaputoUnit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.
Irma SaulleLaboratory of Immunobiology, Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, 20157 Milan, Italy.
Diego ForniScientific Institute IRCCS E. MEDEA, Bioinformatics, Bosisio Parini, 23842 Lecco, Italy.ORCID https://orcid.org/0000-0001-9291-5352
Luis Miguel RealUnidad de Enfermedades Infecciosas y Microbiología Clínica. Hospital Universitario de Valme, 41014 Sevilla, Spain.ORCID https://orcid.org/0000-0003-4932-7429
Juan Antonio PinedaUnidad de Enfermedades Infecciosas y Microbiología Clínica. Hospital Universitario de Valme, 41014 Sevilla, Spain.
Almudena ExpositoUnidad de Inmunogenética, Genética, Departamento de Biología Experimental, Universidad de Jaén, 23071 Jaén, Spain.
María Eugenia SaezCentro Andaluz de Estudios Bioinformáticos, 41092 Sevilla, Spain.
Faruk SinangilGlobal Solutions for Infectious Diseases, Lafayette, 94549 CA, USA.
Donald ForthalDivision of Infectious Diseases, Department of Medicine, University of California, Irvine School of Medicine, Irvine, 92697 CA, USA.
Antonio CaruzUnidad de Inmunogenética, Genética, Departamento de Biología Experimental, Universidad de Jaén, 23071 Jaén, Spain.ORCID https://orcid.org/0000-0002-5788-7840
Mario ClericiDepartment of Physiopathology and Transplantation, University of Milan, 20122 Milan, Italy.ORCID https://orcid.org/0000-0001-5920-6191
IRCCS Eugenio Medea · ITUniversity of Milan · ITCentro de Investigación Biomédica en Red · ESUniversidad de Jaén · ESCentro Andaluz de Biología del Desarrollo · ESGlobal Solutions for Infectious Diseases · USUniversity of California, Irvine · USUniversity of Foggia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An extended haplotype on chromosome 3 is the major genetic risk factor for severe COVID-19. The risk haplotype, which was inherited from Neanderthals, decreases the expression of several cytokine receptors, including CCR5. Recently, a study based on three general population cohorts indicated that the minor allele of one of the variants in the haplotype (rs17713054) protects against HIV infection. We thus expected this allele to be over-represented in highly exposed individuals who remain uninfected (exposed seronegative individuals, ESN). To perform a meta-analysis, we genotyped rs17713054 in three ESN cohorts of European ancestry exposed to HIV through different routes. No evidence of association was detected in the single cohorts. The meta-analysis also failed to detect any effect of the variant on protection from HIV-1. The same results were obtained in a Cox-regression analysis for the time to seroconversion. An in-vitro infection assay did not detect differences in viral replication as a function of rs17713054 genotype status. We conclude that the rs17713054 minor allele is not associated with the ESN phenotype and does not modulate HIV infection in vitro.

Indexed as

COVID-19exposed seronegative individualsgenetic risk factorHIV

Identifiers

PMID36741450
PMCPMC9896871
OpenAlexW4293257104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.